Management of Juvenile Idiopathic Arthritis in ABO-incompatible Kidney Transplantation: A Case Report
Biologic agents are a beneficial therapy for juvenile idiopathic arthritis (JIA). However, there is a lack of evidence with regard to management of these agents for JIA patients who undergo kidney transplantation (KTx). A 36-year-old woman with JIA who was treated with tocilizumab targeting interleukin-6 (IL-6) receptor underwent ABO-incompatible kidney transplantation (ABOi KTx). To prevent over-immunosuppression, tocilizumab was discontinued before ABOi KTx. Rituximab, tacrolimus, mycophenolate mofetil, everolimus, and methylprednisolone were used for immunosuppression. (Source: Transplantation Proceedings)
Source: Transplantation Proceedings - April 1, 2018 Category: Transplant Surgery Authors: S. Ishikawa, M. Tasaki, T. Kuroda, D. Kobayashi, K. Saito, Y. Nakagawa, M. Ikeda, K. Takahashi, Y. Tomita Tags: Original Contributions: Case Reports Source Type: research
Successful Treatment of Cytogenetically Normal Acute Myeloid Leukemia With Ten-Eleven Translocation 2 –Isocitrate Dehydrogenase 2 and Additional Sex Comb-like 1–Nucleophosmin Co-mutations by HLA Haploidentical Stem Cell Transplantation: A Case Report and Literature Review
The presence of recurrent gene mutations is increasingly important in acute myeloid leukemia (AML) and sheds new insights into the understanding of leukemogenesis, prognostic evaluation, and clinical therapeutic efficacy. Until now, ten-eleven translocation 2 (TET2) and isocitrate dehydrogenase 2 (IDH2) mutations were reported to be mutually exclusive in AML patients. Similarly, nucleophosmin (NPM1) and additional sex comb-like 1 (ASXL1) mutations were rarely coexisted in AML. A 47-year-old man diagnosed with high-risk AML presented simultaneous mutations of TET2 –IDH2 and NPM1–ASXL1 revealed by next-generation sequenc...
Source: Transplantation Proceedings - April 1, 2018 Category: Transplant Surgery Authors: Y. Liu, Y. Cao, Y. Lin, W.-M. Dong, R.-R. Lin, Q. Gu, X.-B. Xie, W.-Y. Gu Tags: Original Contributions: Case Reports Source Type: research
Progressive Multifocal Leukoencephalopathy Following Combined Rituximab-Based Immune-Chemotherapy for Post-transplant Lymphoproliferative Disorder in a Renal Transplant Recipient: A Case Report
Transplant recipients are at risk of developing progressive multifocal leukoencephalopathy (PML), an opportunistic infection due to reactivation of JC virus. Post-transplant lymphoproliferative disorders (PTLDs) represent a common malignancy in this population, and antiCD20-therapy has become an established component of its treatment. (Source: Transplantation Proceedings)
Source: Transplantation Proceedings - April 1, 2018 Category: Transplant Surgery Authors: M. Windpessl, S. Burgstaller, A. Kronbichler, H. Pieringer, O. Kalev, A. Karrer, M. Wallner, J. Thaler Tags: Original Contributions: Case Reports Source Type: research
Paradoxical Reaction of Tuberculosis in a Heart Transplant Recipient During Antituberculosis Therapy: A Case Report
Tuberculous paradoxical reactions (PRs) are excessive immune reactions occurring after antituberculosis (TB) treatment and are commonly observed in immunocompromised hosts such as patients infected with the human immunodeficiency virus. (Source: Transplantation Proceedings)
Source: Transplantation Proceedings - April 1, 2018 Category: Transplant Surgery Authors: A. Wakamiya, O. Seguchi, A. Shionoiri, Y. Kumai, K. Kuroda, S. Nakajima, M. Yanase, S. Matsuda, K. Wada, Y. Matsumoto, S. Fukushima, T. Fujita, J. Kobayashi, N. Fukushima Tags: Original Contributions: Case Reports Source Type: research
Ombitasvir –Paritaprevir–Ritonavir Therapy in a Kidney Transplant Recipient With Chronic Hepatitis C Virus Genotype 1 Infection: A Case Report on the Importance of Considering Drug–Drug Interactions and Monitoring Cyclosporine Levels
A 74-year-old Japanese man with a history of chronic hepatitis C and kidney transplant (KT) was administered pegylated-interferon plus ribavirin therapy. However, this therapy was ineffective. The patient was then hospitalized to receive ombitasvir (OBV) plus paritaprevir (PTV) plus ritonavir (r) antiviral combination therapy. He tested negative for the virus after 4 weeks, and completed 12 weeks of treatment. The patient ultimately achieved a sustained virological response after the 12 weeks of treatment. (Source: Transplantation Proceedings)
Source: Transplantation Proceedings - April 1, 2018 Category: Transplant Surgery Authors: S. Takeuchi, M. Takamura, T. Yoshida, K. Takahashi, K. Hayashi, S. Hashimoto, S. Yamagiwa, M. Tasaki, Y. Nakagawa, K. Saito, Y. Tanabe, Y. Tomita, S. Terai Tags: Original Contributions: Case Reports Source Type: research
